Compare RNTX & ELTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RNTX | ELTK |
|---|---|---|
| Founded | 2001 | 1970 |
| Country | United States | Israel |
| Employees | 10 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 53.3M |
| IPO Year | N/A | 1998 |
| Metric | RNTX | ELTK |
|---|---|---|
| Price | $1.17 | $8.10 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 2.6K |
| Earning Date | 05-15-2026 | 05-19-2026 |
| Dividend Yield | N/A | ★ 2.14% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $16.18 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $48.71 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.00 | $7.73 |
| 52 Week High | $2.22 | $12.19 |
| Indicator | RNTX | ELTK |
|---|---|---|
| Relative Strength Index (RSI) | 40.78 | 39.57 |
| Support Level | $1.08 | $7.79 |
| Resistance Level | $1.30 | $9.26 |
| Average True Range (ATR) | 0.15 | 0.31 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 15.45 | 17.89 |
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. The company manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. The geographic areas of the company are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.